Clinical Trial Update: Paclitaxel and Irinotecan in Treating Patients With Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This document reports results from a Phase 2 trial evaluating paclitaxel plus irinotecan in patients with advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Taxol (paclitaxel)

Snippet

Sponsor: Yale University | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED